Skip to Main Content
Phase I

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

  • Study HIC#:2000026742
  • Last Updated:01/01/0001

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Priscilla Stéve

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

    Trial Purpose and Description

    This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

    Eligibility Criteria

    Inclusion Criteria:

    • Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
    • Unresectable or metastatic disease
    • Standard treatment is not available or patient declines
    • Adequate organ function

    Exclusion Criteria:

    • History of intestinal disease or major gastric surgery or inability to swallow oral medications
    • Other active cancer

    For more information about this study, including how to volunteer, contact: